Background {#Sec1}
==========

Although the incidence of gastric cancer has decreased in developed countries, it is the second most common cancer worldwide and two thirds of cases are found in developing countries \[[@CR1]\]. The main sites of metastasis of gastric cancer are the liver and lungs, and the incidence of bone metastasis due to gastric cancer is only 0.9--2.1% \[[@CR2]\], although there may be many gastric cancer patients who have not been diagnosed with metastasis clinically since the reported frequency of bone metastasis in gastric cancer was 13.4--15.9% in an autopsy series \[[@CR3]\].

The median survival times of gastric cancer patients with bone metastasis are 3--4 months after the detection of bone metastasis \[[@CR4], [@CR5]\]. Since bone metastasis can cause intractable pain leading to poor quality of life, appropriate treatment strategies are essential for the affected patients \[[@CR2]\]. Although the clinical characteristics and poor prognostic factors have been reported, they are not well-defined \[[@CR4]--[@CR7]\]. In this study, we retrospectively examined the clinicopathological features, treatment outcomes, and prognostic factors for survival in gastric cancer patients with bone metastasis.

Methods {#Sec2}
=======

This study was approved by the institutional review board at Sakai City Medical Center. We retrospectively collected data on 34 consecutive patients who were radiologically diagnosed with bone metastasis due to gastric cancer between January 2010 and December 2015. All tumors were histologically diagnosed as adenocarcinoma with the stomach, which was recognized as primary tumor. Bone metastases have been treated after the clinical diagnosis by CT, PET-CT, bone scintigraphy, or MRI and after confirming that there were no other suspicious cancers by enhanced CT imaging from the chest to the pelvis. Clinicopathological data, such as age at the diagnosis of bone metastasis, gender, the Eastern Cooperative Oncology Group (ECOG) performance status scale, symptoms at the diagnosis of bone metastasis, tumor localization, differentiation, clinical or pathological stage (according to the 14th edition of the Japanese classification of gastric carcinoma to determine pathological stage \[[@CR8]\]) at initial diagnosis, treatment for primary tumor (surgery or chemotherapy), treatment for bone metastasis (chemotherapy, radiotherapy, or best supportive care), and the spread of bone metastasis, were determined from patient records. The numerical values of serum alkaline phosphatase (ALP), serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA125 were obtained from tests performed at the time of the diagnosis of bone metastasis. When the bone metastasis was observed at the same time as the diagnosis of gastric cancer, we defined it as a synchronous pattern of bone metastasis, while a metachronous pattern of bone metastasis was defined as bone metastasis detected at any time after the diagnosis of gastric cancer. For some patients, only a computed tomography (CT) scan was used in the diagnosis because bone metastasis was evident, while many patients were diagnosed using a combination of bone scintigraphy, positron emission tomography (PET)-CT, and magnetic resonance imaging (MRI).

We estimated the overall survival after the diagnosis of bone metastasis using the Kaplan-Meier product-limit method. We also evaluated which clinicopathological factors were associated with prognostic factors for survival using univariate and multivariate Cox proportional hazards regression models. Statistical significance was set at *p* \< 0.05. All statistical analyses were performed using SPSS Statistics software, version 19 (IBM Corp., Armonk, NY, USA).

Results {#Sec3}
=======

The median age of the 34 patients at the time the bone metastasis was diagnosed was 66 years (Table [1](#Tab1){ref-type="table"}). There were 26 male patients and 8 females, and 19 patients (55.9%) had undifferentiated adenocarcinoma. The treatment for the primary tumor was surgery in 16 patients (47.1%), and 10 of them had radical resection. Out of 18 patients (52.9%) who used chemotherapy for initial treatment, 2 patients had surgery after chemotherapy with S1 and cisplatin. Eleven patients (32.4%) had bone pain at the time the bone metastasis was diagnosed. The median serum ALP and LDH levels at the time of bone metastasis were 375.5 and 249 IU/L, respectively. To diagnose the bone metastasis, CT scan was used for 30 patients (29.4%), and 15 patients of them underwent bone scintigraphy (9 patients), MRI (7 patients), and PET-CT (1 patient) after CT scan (Two patients underwent both bone scintigraphy and and MRI).Table 1Patient demographics and pathologic featuresFactorsPatient\
(*n* = 34)Age (years)Median (range)66 (39--78)GenderMale26 (76.5%)Female8 (23.5%)ECOG performance status0--116 (47.1%)2--418 (52.9%)Bone painPresent11 (32.4%)Absent23 (67.6%)LocationUpper 1/35 (14.7%)Middle 1/317 (50.0%)Lower 1/35 (14.7%)Whole stomach7 (20.6%)Histologic typeDifferentiated15 (44.1%)Undifferentiated19 (55.9%)Stage^a^I1 (2.9%)II3 (8.8%)III8 (23.5%)IV22 (64.7%)Treatment for primary tumorSurgery16 (47.1%)Chemotherapy18 (52.9%)ALP (IU/L)Median (range)375.5 (157--2743)LDH (IU/L)Median (range)249 (117--1481)CEAMedian (range)8.6 (1.0--3508)CA19-9Median (range)53.7 (0.6--1814.0)CA125Median (range)20.3 (7.9--1099)Diagnostic modalityCT30 (88.2%)Bone scan10 (29.4%)MRI9 (26.5%)PET-CT1 (2.9%)Pattern of bone metastasisSynchronous10 (29.4%)Metachronous24 (70.6%)Number of bone metastasesSingle12 (35.3%)Multiple22 (64.7%)Extraosseous metastasisPresent26 (76.5%)Absent8 (23.5%)Treatment of bone metastasisChemotherapy26 (76.5%)Radiotherapy5 (14.7%)Best supportive care4 (11.8%)*Abbreviations*: *ALP* serum alkaline phosphatase, *LDH* lactate dehydrogenase, *CEA* serum carcinoembryonic antigen, *CA* carbohydrate antigen, *CT* computed tomography, *MRI* magnetic resonance imaging, *PET* positron emission tomography^a^Stage was according to the 14th edition of the Japanese classification of gastric carcinoma

Ten patients (29.4%) were diagnosed with bone metastasis and gastric cancer at the same time, and 26 patients (76.5%) had at least one other organ affected besides their bones. Of the 24 patients who had metachronous metastasis, the median interval from the diagnosis of gastric cancer to the detection of bone metastasis was 398 days (range, 43--1799, data not shown).

The treatment of the bone metastasis consisted of chemotherapy in 26 patients (76%), radiotherapy in 5 patients (15%), and 4 patients only received the best supportive care (12%). The most common sites of bone metastases were the thoracic vertebrae (55.9%), pelvic bones (41.2%), lumbar vertebrae (38.2%), and ribs (29.4%) (Table [2](#Tab2){ref-type="table"}). Many patients were treated with chemotherapy, such as S1-based regimens, as first-line chemotherapy, and taxane-based or irinotecan-based regimens as second and subsequent chemotherapies, according to the recommendation of the Japanese Gastric Cancer Treatment Guidelines for patients who have progressive or recurrent gastric cancer \[[@CR9]\]. Some patients were treated with radiotherapy for a localized tumor or local symptom relief.Table 2Site of bone metastasisSite of bone metastasisPatient\
(*n* = 34)Thoracic vertebrae19 (55.9%)Pelvic bones14 (41.2%)Lumbar vertebrae13 (38.2%)Ribs10 (29.4%)Cervical vertebrae6 (17.6%)Calvarium4 (11.2%)Scapula3 (8.8%)Lower extremity3 (8.8%)Upper extremity2 (5.9%)Clavicle1 (2.9%)Sternum1 (2.9%)

The 6-month survival rate and the median survival time after the diagnosis of bone metastasis were 63.8% and 227.5 days, respectively (Fig. [1](#Fig1){ref-type="fig"}). A multivariate analysis revealed that metachronous metastasis (odds ratio 3.6; 95% confidence interval 1.1--11.7; *p* = 0.035) and extraosseous metastasis (odds ratio 4.1; 95% confidence interval 1.2--14.9; *p* = 0.028) were significant risk factors for poor survival (Table [3](#Tab3){ref-type="table"}).Fig. 1Overall survival of patients after the diagnosis of bone metastasis Table 3Univariate and multivariate analyses of prognostic factors for survivalUnivariate analysisMultivariate analysisRR (95% CI)*p* valueRR (95% CI)*p* valueAge≥75\<751.8 (0.25--13.7)0.54GenderMaleFemale1.1 (0.45--2.9)0.78ECOG performance status0--12--41.4 (0.57--3.4)0.481.1 (0.41--2.8)0.88Bone painAbsentPresent2.0 (0.90--4.5)0.0912.7 (0.93--8.1)0.068Histologic typeUndifferentiatedDifferentiated1.1 (0.53--2.5)0.73Stage^a^I--IIIIV1.0 (0.46--2.2)0.99Pattern of bone metastasisSynchronousMetachronous2.8 (1.1--7.5)0.0383.6 (1.1--11.7)0.035Extraosseous metastasisAbsentPresent1.1 (0.47--2.8)0.774.1 (1.2--14.9)0.028*Abbreviations*: *CI* confidential interval, *ECOG* Eastern Cooperative Oncology^a^Stage was according to the 14th edition of the Japanese classification of gastric carcinoma

Discussion {#Sec4}
==========

In this study, the 6-month survival rate and the median survival time after the diagnosis of bone metastasis were 63.8% and 227.5 days, respectively. In univariate analysis, only pattern of bone metastases (synchronous vs metachronous) became an independent prognostic factor. The multivariate analysis was carried out using the pattern of bone metastases and variables pointed out to affect prognosis in past reports \[[@CR2], [@CR7]\]. As a result, metachronous metastasis and extraosseous metastasis were significant risk factors for poor survival.

In the period of this study, there were 622 patients who have been treated for gastric cancer for the first time in our hospital, and 34 of them have been diagnosed with bone metastasis. Most patients develop bone metastasis within 2 years of gastric surgery \[[@CR3]\]. In this study, the median interval from the diagnosis of gastric cancer to the detection of bone metastasis was 398 days in the patients who had metachronous metastasis, and the median interval from the surgery to the detection of bone metastasis was 562 days. Bone metastases from gastric cancer were not unusual in a multicenter trial \[[@CR10]\], and Turkoz et al. suggested that bone metastases should be considered during the follow-up of gastric cancer patients, even in the early period \[[@CR3]\]. Patients may have relatively long-term survival if there is no extraosseous metastasis or local control for metastasis is possible, but it is difficult to diagnose bone metastasis because the majority of affected patients are asymptomatic and evaluations for bone metastases are not indicated in routine practice \[[@CR7]\]. In our study, there were many cases that were discovered by chance during a routine CT examination. Only 32.4% of patients complained about symptoms, such as bone pain. In addition, serum ALP, LDH, or tumor markers were not always high, although there have been several reports that show such serum parameters were useful for diagnosing bone metastasis \[[@CR11]--[@CR13]\]. Ahn et al. suggested that an appropriate modality, such as bone scintigraphy, is required to assess bone metastasis at the time of the initial diagnosis and during follow-up observations \[[@CR5]\].

Since there were no prospective studies of therapeutic regimens in gastric cancer patients with bone metastasis, the optimal chemotherapy regimens were unknown \[[@CR2]\]. In this study, the treatment of metachronous bone metastasis differed depending on the judgment of the attending physician, and there had been various treatments before bone metastasis was recognized, while median survival time (MST) of patients who were treated metachronous bone metastasis with S1-based regimens or irinotecan-based regimens was significantly longer than MST of other patients (314 vs 87 days, *p* = 0.010). The Japanese Gastric Cancer Treatment Guidelines recommend S1-based chemotherapy for progressive or recurrent gastric cancer \[[@CR9]\]. On the other hand, since bone metastasis can cause disseminated intravascular coagulation (DIC), the poor general condition of the patient or the presence of thrombocytopenia and severe anemia may make the patient ineligible for chemotherapy \[[@CR14]\]. Hironaka et al. reported that sequential methotrexate and 5-fluorouracil chemotherapy resulted in a high rate of alleviation of DIC caused by bone metastasis from gastric cancer \[[@CR15]\]. In addition, the pain management for patients with bone pain is important and radiation therapy may be quite effective \[[@CR5]\]. In recent years, it has been reported that the incidence of epidermal growth factor receptor (EGFR) mutations in the bone metastases was high in the lung adenocarcinoma \[[@CR16], [@CR17]\]. Thus, EGFR tyrosine kinase inhibitor therapies could be effective for the type of adenocarcinoma. However, there are no reports about genetic mutations in the bone metastases due to gastric cancer. Identifying such mechanisms like gene mutations may lead to the development of future treatment.

In our study, the diagnosis of bone metastasis was left to the discretion of the attending physician and various modalities were used, so we could not evaluate which diagnostic methods were appropriate. In addition, the treatments varied depending on when the bone metastasis was detected. Therefore, further investigations are necessary.

Conclusions {#Sec5}
===========

The prognosis of gastric cancer with bone metastasis was poor, and metachronous metastasis and extraosseous metastasis were shown to be poor prognostic factors. In addition, ALP, LDH, and tumor markers are not always high, so aggressive diagnosis using appropriate modalities such as bone scan, MRI, or PET-CT may be necessary in routine practice even in asymptomatic patients.
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